J&J’s Caplyta label expansion in depression fuels push toward $5B goal

A label expansion in major depressive disorder could help J&J fulfill the sales goal it has set for Caplyta, the therapy at the center of its $14.6 billion acquisition of Intra-Cellular this year.

Major depressive disorder (MDD) is the fourth approved indication for Caplyta lumateperone, after bipolar depression in two settings and schizophrenia. At the Piper Sandler Healthcare Conference in December 2024, Intra-Cellular Therapies Inc. EVP and Chief Commercial Officer Mark Neumann said MDD and bipolar depression are “the two big indications” for Caplyta, with schizophrenia accounting for “much less” of the drug’s peak sales opportunity...